Rational Pharmacotherapy in Cardiology

Advanced search

Anticoagulant Therapy in “Fragile” Elderly Patients: Current State of the Problem

Full Text:


The review focuses on the use of oral anticoagulants in fragile elderly patients. The issues of prevalence and diagnosis of senile asthenia syndrome or “fragility”, as well as its effects on the risks of thrombosis, bleeding and death, are discussed. The evidence base, which is quite limited, for the participation of fragile elderly patients in randomized controlled trials and real clinical practice trials with direct oral anticoagulants is presented. Nevertheless, one of the studies of real clinical practice showed that only therapy with rivaroxaban (out of three direct oral anticoagulants) compared with warfarin reduced the risk of stroke/systemic embolism and ischemic stroke alone in fragile elderly patients with atrial fibrillation after 2 years of observation.

About the Authors

N. M. Vorobyeva
Pirogov Russian National Research Medical University
Russian Federation
MD, PhD, Head of Laboratory of Cardiovascular Aging, Russian Gerontology Clinical Research Center

O. N. Tkacheva
Pirogov Russian National Research Medical University
Russian Federation
MD, PhD, Professor, Director of Russian Gerontology Clinical Research Center


1. Nichols M., Townsend N., Scarborough P., Rayner M. Cardiovascular disease in Europe: epidemiological update. Eur Heart J. 2013;34:3028-34. doi:10.1093/eurheartj/eht356.

2. Aronow W.S. Approach to symptomatic coronary disease in the elderly: TIME to change? Lancet. 2001;358:945-6. doi:10.1016/S0140-6736(01)06111-6.

3. Dolan G., Neal K., Cooper P. et al. Protein C, antithrombin III and plasminogen: effect of age, sex and blood group. Br J Haematol. 1994;86:798-803. doi:10.1111/j.1365-2141.1994.tb04832.x.

4. Gleerup G., Winther K. The effect of ageing on platelet function and fibrinolytic activity. Angiology. 1995;46:715-8.

5. Wilkerson W.R., Sane D.C. Aging and thrombosis. Semin Thromb Hemost. 2002;28:555-68. doi:10.1055/s-2002-36700.

6. Simmonds M.J., Meiselman H.J., Baskurt O.K. Blood rheology and aging. J Geriatr Cardiol. 2013;10:291-301. doi:10.3969/j.issn.1671-5411.2013.03.010.

7. Go A.S., Mozaffarian D., Roger V.L. et al. Heart disease and stroke statistics - 2014 update: a report from the American Heart Association. Circulation. 2014;129(3):e28-e292. doi:10.1161/01.cir.0000441139.02102.80.

8. Fried L.P., Borhani N.O., Enright P. et al. The Cardiovascular Health Study: design and rationale. Ann Epidemiol. 1991;1:263-76.

9. Fried L.P., Tangen C.M., Walston J. et al. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci. 2001;56(3):146-56.

10. Searle S.D., Mitnitski A., Gahbauer E.A. et al. A standard procedure for creating a frailty index. BMC Geriatr. 2008;8:24. doi:10.1186/1471-2318-8-24.

11. Tkacheva O.N., Runikhina N.K., Ostapenko V.S. et al. Validation of the questionnaire for screening of a syndrome of a senile asthenia in outpatient practice. Uspekhi Gerontologii. 2017;30(2):236-42 (In Russ.) 12. Collard R.M., Boter H., Schoevers R.A., Oude Voshaar R.C. Prevalence of frailty in community dwelling older persons: a systematic review. J Am Geriatr Soc. 2012;60(8):1487-92. doi:10.1111/j.1532-5415.2012.04054.x.

12. Gurina N.A., Frolova E.V., Degryse J.M. A roadmap of aging in Russia: the prevalence of frailty in community-dwelling older adults in the St. Petersburgdistrict-the “Crystal” study. Jam Geriatr Soc. 2011;59(6):980-8. doi:10.1111/j.1532-5415.2011.03448.x.

13. Fried L.P., Ferrucci L., Darer J. et al. Untangling the concepts of disability, frailty, and comorbidity: implications for improved targeting and care. J Gerontol A Biol Sci Med Sci. 2004;59:255-63.

14. Bales C.W., Ritchie C.S. Sarcopenia, weight loss, and nutritional frailty in the elderly. Annu Rev Nutr. 2002;22:309-23. doi:10.1146/annurev.nutr.22.010402.102715.

15. Hubbard R.E., Andrew M.K., Rockwood K. Effect of parental age at birth on the accumulation of deficits, frailty and survival in older adults. Age Ageing. 2009;38:380-5. doi:10.1093/ ageing/afp035.

16. Walston J., McBurnie M.A., Newman A. et al.; Cardiovascular Health Study. Frailty and activation of the inflammation and coagulation systems with and without clinical comorbidities: results from the Cardiovascular Health Study. Arch Intern Med. 2002;162:2333-41. doi:10.1001/archinte. 162.20.2333.

17. Marzona I., O’Donnell M., Teo K. et al. Increased risk of cognitive and functional decline in patients with atrial fibrillation: results of the ONTARGET and TRANSCEND studies. CMAJ. 2012;184(6): E329-E336. doi:10.1503/cmaj.111173.

18. Kim S., Yoon S., Choi J. et al. Clinical implication of frailty assessment in older patients with atrial fibrillation. Archives of Gerontology and Geriatrics. 2017;70:1-7. doi:10.1016/j.archger. 2016.12.001.

19. Perera V., Bajorek B.V., Matthews S. et al. The impact of frailty on the utilisation of antithrombotic therapy in older patients with atrial fibrillation. Age Ageing. 2009;38:156-62. doi:10.1093/ageing/afn293.

20. Induruwa I., Evans N.R., Aziz A. et al. Clinical frailty is independently associated with non-prescription of anticoagulants in older patients with atrial fibrillation. Geriatr Gerontol Int. 2017;17(11):2178-83. doi:10.1111/ggi.13058.

21. Buller H.R., Prins M.H., Lensin A.W. et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med. 2012;366:1287-97. doi:10.1056/NEJMoa1113572.

22. Prins M.H., Lensing A.W., Bauersachs R. et al., EINSTEIN Investigators. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thromb J. 2013;11:21. doi:10.1186/1477-9560-11-21.

23. Coleman C.I., Turpie A.G.G., Bunz T.J., Beyer-Westendorf J. Effectiveness and Safety of Rivaroxaban Versus Warfarin in Frail Patients with Venous Thromboembolism. The American Journal of Medicine. 2018;131(8):933-8.e1. doi:10.1016/j.amjmed.2018.02.015.

24. Martinez B.K., Sood N.A., Bunz T.J., Coleman C.I. Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Frail Patients With Nonvalvular Atrial Fibrillation. J Am Heart Assoc. 2018;7:e008643. doi:10.1161/JAHA.118.008643.

25. Herr M., Robine J.-M., Pinot J. et al. Polypharmacy and frailty: prevalence, relationship, and impact on mortality in a French sample of 2350 old people. Pharmacoepidemiology and Drug Safety. 2015; 24 (6): 637-646. doi:10.1002/pds.3772.

26. Piccini J.P., Hellkamp A.S., Washam J.B. et al. Polypharmacy and the Efficacy and Safety of Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation. Circulation. 2015;133(4):352-60. doi:10.1161/circulationaha.115.018544.

For citation:

Vorobyeva N.M., Tkacheva O.N. Anticoagulant Therapy in “Fragile” Elderly Patients: Current State of the Problem. Rational Pharmacotherapy in Cardiology. 2018;14(6):908-916.

Views: 661

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.

ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)